Found 1 Presentation For Request "1263p"
1263P - Tislelizumab + chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous NSCLC
- Shun Lu (Shanghai, China)
Abstract
Background
Tislelizumab + chemotherapy has shown antitumor activity with a favorable tolerability profile in patients (pts) with histologically confirmed nsq-NSCLC.
Methods
In this open-label phase 3 study (NCT03663205), Chinese pts were randomized 2:1 to receive tislelizumab 200 mg + platinum (carboplatin AUC 5 or cisplatin 75 mg/m2) + pemetrexed 500 mg/m2, followed by maintenance tislelizumab + pemetrexed (
Results
As of 23 Jan 2020, 334 pts with nsq-NSCLC (
Conclusions
Tislelizumab plus chemotherapy was generally well tolerated and demonstrated antitumor activity in pts with nsq-NSCLC.
Clinical trial identification
NCT03663205.
Editorial acknowledgement
Writing and editorial assistance was provided by Stephan Lindsey, PhD, and Elizabeth Hermans, PhD (OPEN Health Medical Communications, Chicago. IL), and funded by the study sponsor.
Legal entity responsible for the study
This study was sponsored by BeiGene, Ltd.
Funding
BeiGene, Ltd.
Disclosure
S. Lu: Research grant/Funding (institution): AstraZeneca BMS, Hutchison, BMS, Heng Rui, and Roche; Speaker Bureau/Expert testimony: AstraZeneca, Roche, Hanseng; Advisory/Consultancy: AstraZeneca, Boehringer Ingelheim, Hutchison Medipharma, Simcere, and Roche. Y. Sun: Speaker Bureau/Expert testimony: AstraZeneca, Roche. Y. Bao, L. Liang: Full/Part-time employment: BeiGene, Ltd. All other authors have declared no conflicts of interest.